J Vis Exp:基于质谱的蛋白质组学样品制备分析眼部微血管

2019-04-30 不详 网络

美因茨约翰内斯古腾堡大学医学中心眼科的Perumal N等人近日在J Vis Exp杂志上发表了一篇文章,他们优化了眼部微血管质谱分析的样本制备流程。

美因茨约翰内斯古腾堡大学医学中心眼科的Perumal N等人近日在J Vis Exp杂志上发表了一篇文章,他们优化了眼部微血管质谱分析的样本制备流程。

使用先进的技术方法在体外分离眼部血管来破译眼睛的生理病理状态,这极大地扩展了我们对某些疾病的理解。基于质谱(MS)的蛋白质组学已经成为解释健康和疾病状态下血管分子机制和蛋白质信号传导途径改变的有力工具。然而,MS分析前的样品制备步骤对于获得可重复的实验结果十分重要,同时对复杂蛋白质组的深入阐明也是至关重要。这对于眼部微血管的制备尤其重要,其中可用于分析的样品量通常是有限的,因此对蛋白质的最佳量提取提出了挑战。

本文从猪睫状体后动脉提取蛋白进行质谱分析,作为眼球后血管有效、快速和稳健的样品制备方案案例。本方法在均质化后样品上清液和沉淀物的蛋白质提取程序上进行完善,在一维凝胶电泳之前用离心过滤装置清洗样品,在液相色谱 - 电喷雾电离中进行无标记定量的肽纯化步骤,即线性离子阱Orbitrap MS系统优化。

最后,作者总结称虽然这种方法是专门针对眼部微血管的蛋白质组学分析而开发的,但也提供了令人信服的证据,表明它也可以很容易地用于其他组织的样品。

原文出处:

Perumal, N., et al., Sample Preparation for Mass-spectrometry-based Proteomics Analysis of Ocular Microvessels. J Vis Exp, 2019(144).

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
    2020-01-29 huiwelcome
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
    2019-05-02 mgqwxj
  7. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
    2019-05-02 jeanqiuqiu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
    2019-05-01 王秀

    学习了,涨知识了!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1765777, encodeId=62371e65777a8, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Feb 04 09:35:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776089, encodeId=cefc1e76089a9, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Wed Jan 29 20:35:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754846, encodeId=02601e5484613, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Fri Oct 18 01:35:00 CST 2019, time=2019-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800712, encodeId=22251800e1298, content=<a href='/topic/show?id=5548e292155' target=_blank style='color:#2F92EE;'>#眼部微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72921, encryptionId=5548e292155, topicName=眼部微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Aug 09 21:35:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297081, encodeId=8faf129e081ba, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365372, encodeId=87b013653e267, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553349, encodeId=aede155334984, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu May 02 13:35:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365568, encodeId=09c5365568b6, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Wed May 01 14:52:07 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365562, encodeId=23bb36556298, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed May 01 11:14:07 CST 2019, time=2019-05-01, status=1, ipAttribution=)]
    2019-05-01 txqjm

    谢谢了,学习

    0

相关资讯

Sci Transl Med:基于一种靶向质谱的高通量技术快速验证潜在的癌症标记分子

来自瑞士苏黎世联邦理工学院的研究人员开发出一种方法来测试癌症生物标记分子的临床意义。这种方法能够显著性地加快实验室发现的癌症标记物的应用。 由于蛋白质组和基因组研究以及利用计算机为生物过程建模上取得的巨大进展,研究人员在最近几年已发现一千多种潜在的蛋白生物标记分子。生物标记分子的候选物名单也变得越来越长。然而,在文献中提出和记录的大多数蛋白生物标记分子并没有用于临床应用中。将人们开发出的新生物标

Exp Eye Res:猪体内磷脂玻璃体液中的区域分布研究

美国路易斯维尔大学眼科与视觉科学系的Borchman D教授团队近日在Exp Eye Res杂志上发表了他们最新的一项工作,他们研究了猪体内磷脂玻璃体液中的区域分布情况。

CCLM:通过电感耦合等离子体质谱法测定血清钾

钾是临床实验室经常测定的重要血清离子。需要特定的参考方法来保证检测质量; 因此,建立血清钾测量的候选参考方法是非常重要的。研究人员开发了一种电感耦合等离子体质谱(ICP-MS)方法。用铝作为内参对血清样品重量分析,用69%超纯硝酸消化,并稀释至所需浓度。在在氢气模式下通过ICP-MS测定39 K / 27 Al比。该方法使用5%硝酸基质校准器进行校准,并使用多重曝光法建立校准功能。

SCI REP:基于氨基酸代谢的差异,通过质谱快速鉴别人食管鳞状细胞癌

我们显示iEESI-MS与PLS联合可以用于成功地原位和实时地识别肿瘤组织。 此外,我们发现二甲基甘氨酸,脯氨酸,异亮氨酸,天冬酰胺,异亮氨酸和精氨酸可能是与EC发展相关的分子生物标志物。 组织氨基酸的进一步研究可能使我们更好地了解OC中涉及的潜在机制,并开发出鉴定手术中肿瘤组织的新手段。

CCLM:通过超高效液相色谱串联质谱法评估大麻茶和大麻油标准化制剂中大麻素的浓度和稳定性

近日,国际杂志《Clinical Chemistry and Laboratory Medicine》在线发表了一篇关于通过超高效液相色谱串联质谱法评估大麻茶和大麻油标准化制剂中大麻素的浓度和稳定性的研究。 从古以来,大麻一直被用于缓解神经性疼痛,降低眼内压,增加食欲,以减少恶心和呕吐。精神活性大麻生物碱Δ9-四氢大麻酚(THC)与非精神药物生物碱大麻二酚(CBD)和大麻酚(CBN)的组合显示出